Bayer (BAYRY)
(Delayed Data from OTC)
$8.09 USD
+0.35 (4.52%)
Updated Aug 1, 2025 03:59 PM ET
2-Buy of 5 2
A Value D Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Bayer Aktiengesellschaft has a PEG ratio of 0.08 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.71.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BAYRY 8.09 +0.35(4.52%)
Will BAYRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAYRY
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Q2 Reports Shape a More Uncertain Outlook?
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
Best Value Stocks to Buy for July 22nd
Other News for BAYRY
Bayer gains after raising 2025 outlook
Regeneron posts Q2 beat as new Eylea version outperforms
EU pharma lobby criticizes potential Trump tariffs on pharmaceuticals
Bayer says FDA extends review period for elinzanetant NDA
Bayer's elinzanetant review period gets extended by FDA